Robert Z. Orlowski, MD, PhD, director of the Myeloma Section at the University of Texas MD Anderson Cancer Center, reviewed novel agents in the treatment of triple-class refractory myeloma during a session at the 2021 annual meeting of the Society of Hematologic Oncology (SOHO).
The recommendation for managing cytopenias among patients treated with tyrosine kinase inhibitors is to discontinue treatment at the onset of grade 3 or higher.
The combination of cetuximab and encorafenib resulted in a median overall survival of 8.4 months, compared to 5.4 months in the control arm among patients with colorectal cancer.
Although specialty pharmacies may be able to offer some of the services that a hub provider does, a hub can standardize patient and provider support across the network.
Amisulpride is a selective dopamine-2 and -3 receptor antagonist that inhibits postoperative nausea and vomiting.
Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses the areas that may need further investigation to progress advanced cutaneous T cell lymphoma treatments in the future.
Risk stratification for survival should not dictate treatment, but stratification for thrombosis risk should play an important role in treatment decisions.
Cemiplimab-rwlc is being developed by Regeneron and Sanofi under a global collaboration agreement.
Durvalumab in combination with oleclumab reduced the risk of non-small cell lung cancer disease progression or death by 56%, whereas patients receiving durvalumab and monalizumab had a 35% reduction.
The results were compared to those in the previous Pfizer-BioNTech study in people between 16 and 25 years of age who were immunized with 30 μg doses.
The combination maintained superior OS and response benefits versus sunitinib in both patients with intermediate- and poor-risk prognostic factors, the primary endpoint population, and across all randomized patients.
Vascepa is indicated to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients.
Hans Eriksson, MD, PhD, the chief clinical development officer at HMNC Brain Health, on the development of personalized treatments for neuropsychiatric disorders using precision-medicine.
Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explains what research is underway in the advanced cutaneous T cell lymphoma field that she is currently keeping an eye on.
By deactivating a component of the MAPK signaling pathway, researchers were able to reduce the proportion of leukemia cells in blood and bone marrow.
Shawn Singh, CEO of VistaGen, discusses how to improve and more effectively treat mental health disorders for returning veterans, who currently account for 20% of all suicides in the United States.
Treatment of round pneumonia should be followed up with a 2-view chest X-ray weeks later.
Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), discusses the SHC’s recently released Flu DRIVE Toolkit, which was designed to help overburdened health systems improve flu vaccination rates among vulnerable populations.
An intravenous immunoglobulin option along with glucocorticoids could be effective in fighting drug-induced erythroderma for patients with AIDS.
Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, describes some of the challenges providers face during the treatment of patients with advanced cutaneous T cell lymphoma and how to address them.
Treatment with neoadjuvant cisplatin and pemetrexed plus atezolizumab for pleural mesothelioma found to be safe in trial.
Although there are several conditions known to be risk factors for clostridium difficile, data on the link between malignancy and clostridium difficile are limited.
Enfortumab vedotin-ejfv (Seagen; Padcev) is a first-in-class antibody-drug conjugate approved for patients with previously treated locally advanced or metastatic urothelial cancer.
The prostate-specific membrane antigen-targeted positron emission tomography imaging technique will be part of the National Comprehensive Cancer Network guidelines beginning in 2022.
Although frontotemporal dementia is the leading cause of the disease for those under 65 years of age, far fewer people are familiar with it than with Alzheimer disease.
Study shows Lefamulin, omadacycline, ceftaroline, delafloxacin are beneficial in treating community-acquired pneumonia.
Ribociclib is an inhibitor of cyclin-dependent kinase 4 and 6 and causes tumor growth inhibition.
Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses how the treatment of advanced cutaneous T cell lymphoma has changed in recent years and whether there have been any advancements of note.
Andrea Silber, MD, said the COVID-19 pandemic has exacerbated disparities that already existed within oncology care, and she said the effects of these disparities on patients are very real and direct.
The overall response rate of ruxolitinib at week 24 was 49.7% compared with 25.6% for the best available therapy treatment for graft-versus-host-disease.
